In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish.
Latest Ratings for ACAD
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Cantor Fitzgerald | Maintains | Overweight | |
| Mar 2022 | Goldman Sachs | Maintains | Neutral | |
| Mar 2022 | Mizuho | Maintains | Neutral |
